Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

BioAtla Building China Antibody Ops As It Eyes IPO

This article was originally published in PharmAsia News

Executive Summary

BioAtla has entered a strategic and option agreement with Pfizer to develop a new class of antibody therapeutics, and plans to continue working with BioDuro as part of its R&D plans and efforts in China, which include a manufacturing site in Hefei. Meanwhile, BioAtla is also eyeing a possible IPO on Nasdaq next year.



Related Companies